

Targeting ceramide synthase 6–dependent metastasis-prone phenotype in lung cancer cells

Motoshi Suzuki, Ke Cao, Seiichi Kato, Yuji Komizu, Naoki Mizutani, Kouji Tanaka, Chinatsu Arima, Mei Chee Tai, Kiyoshi Yanagisawa, Norie Togawa, Takahiro Shiraishi, Noriyasu Usami, Tetsuo Taniguchi, Takayuki Fukui, Kohei Yokoi, Keiko Wakahara, Yoshinori Hasegawa, Yukiko Mizutani, Yasuyuki Igarashi, Jin-ichi Inokuchi, Soichiro Iwaki, Satoshi Fujii, Akira Satou, Yoko Matsumoto, Ryuichi Ueoka, Keiko Tamiya-Koizumi, Takashi Murate, Mitsuhiro Nakamura, Mamoru Kyogashima, Takashi Takahashi

J Clin Invest. 2019;129(8):3464–3464. <https://doi.org/10.1172/JCI131245>.

Expression of concern

Original citation: *J Clin Invest.* 2016;126(1):254–265. <https://doi.org/10.1172/JCI79775> Citation for this expression of concern: *J Clin Invest.* 2019;129(8):3464 <https://doi.org/10.1172/JCI131245> The corresponding author recently notified the JCI that the patient data presented in Figure 1B were not correct. Analysis of the correct patient data set does not show a significant difference in CERS6 expression in human lung adenocarcinomas with positive invasive growth (definite) compared with those with negligible invasive growth or without invasive growth (focal/none). The Editors have requested an institutional investigation into this matter, and we will inform our readers of the outcome when the investigation is complete.

Find the latest version:

<https://jci.me/131245/pdf>



Expression of Concern

Targeting ceramide synthase 6–dependent metastasis-prone phenotype in lung cancer cells

Motoshi Suzuki, Ke Cao, Seiichi Kato, Yuji Komizu, Naoki Mizutani, Kouji Tanaka, Chinatsu Arima, Mei Chee Tai, Kiyoshi Yanagisawa, Norie Togawa, Takahiro Shiraishi, Noriyasu Usami, Tetsuo Taniguchi, Takayuki Fukui, Kohei Yokoi, Keiko Wakahara, Yoshinori Hasegawa, Yukiko Mizutani, Yasuyuki Igarashi, Jin-ichi Inokuchi, Soichiro Iwaki, Satoshi Fujii, Akira Satou, Yoko Matsumoto, Ryuichi Ueoka, Keiko Tamiya-Koizumi, Takashi Murate, Mitsuhiro Nakamura, Mamoru Kyogashima, and Takashi Takahashi

Original citation: *J Clin Invest*. 2016;126(1):254–265. <https://doi.org/10.1172/JCI9775>.

Citation for this expression of concern: *J Clin Invest*. 2019;129(8):3464. <https://doi.org/10.1172/JCI131245>.

The corresponding author recently notified the *JCI* that the patient data presented in Figure 1B were not correct. Analysis of the correct patient data set does not show a significant difference in *CERS6* expression in human lung adenocarcinomas with positive invasive growth (definite) compared with those with negligible invasive growth or without invasive growth (focal/none). The Editors have requested an institutional investigation into this matter, and we will inform our readers of the outcome when the investigation is complete.

Expression of Concern

Tandem CAR T cells targeting HER2 and IL13R α 2 mitigate tumor antigen escape

Meenakshi Hegde, Malini Mukherjee, Zakaria Grada, Antonella Pignata, Daniel Landi, Shoba A. Navai, Amanda Wakefield, Kristen Fousek, Kevin Bielamowicz, Kevin K.H. Chow, Vita S. Brawley, Tiara T. Byrd, Simone Krebs, Stephen Gottschalk, Winfried S. Wels, Matthew L. Baker, Gianpietro Dotti, Maksim Mamonkin, Malcolm K. Brenner, Jordan S. Orange, and Nabil Ahmed

Original citation: *J Clin Invest*. 2016;126(8):3036–3052. <https://doi.org/10.1172/JCI83416>.

Citation for this expression of concern: *J Clin Invest*. 2019;129(8):3464. <https://doi.org/10.1172/JCI131246>.

A reader recently alerted the *Journal* that two images in this *JCI* article appear similar to images subsequently published in a *Neuro-Oncology* paper from the same lab as unique samples (1). Specifically, in Figure 9D of the *JCI* paper, the image for IL13R α 2 staining for the HER2 CAR sample appears to be similar to the image for EphA2 staining of a nontransduced T cell-treated sample published in Figure 6A of the *Neuro-Oncology* paper. In addition, in Figure 9D of the *JCI* paper, the image for IL13R α 2 staining for the tumor sample appears to be similar to the image for HER2 staining of a nontransduced T cell-treated sample in Figure 6B of the *Neuro-Oncology* paper. An institutional investigation into this matter is ongoing, and we will inform our readers of the outcome when the investigation is complete.

1. Bielamowicz K, et al. Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma. *Neuro Oncol*. 2018;20(4):506–518.